Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Expands Outsourcing With Zhejiang Huahai For HIV Finished Product Manufacturing

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's leading contract manufacturing company and API provider Zhejiang Huahai announced March 8 that the company has reached a drug supply agreement with Merck to produce finished drugs for the next several years

You may also be interested in...



China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts

SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing

China's State FDA Imposes New Regulatory Requirements On CMOs And Third-party Contracts

SHANGHAI - In a bid to prevent the export of counterfeit medicines, China is tightening its supervision of contract manufacturing organizations doing work for overseas drug makers. To that end, China's State FDA recently issued a notice on new rules governing cross-border contract manufacturing

New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World

CAMBRIDGE, Mass. - Life science companies looking to provide healthcare solutions to the poorer, "bottom of the pyramid" - a population reaching more than 600 million people in India alone - should focus on business model innovation as much as on innovative products, according to delegates at the U.S.-India Chamber of Commerce biopharmaceutical and healthcare summit in Cambridge, Mass

Related Content

UsernamePublicRestriction

Register

SC074270

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel